Peptide Amide Oral Composition for Moisture-Stable Pain Tablets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral formulations of peptide amide compounds like compound A suffer from instability, impurity formation due to moisture sensitivity, and poor stability, which affects their efficacy and safety for treating chronic pain and pruritus.
Innovation Solution
An oral pharmaceutical composition of compound A is prepared using a combination of microcrystalline cellulose colloidal silica co-treatment substance and pregelatinized starch, along with disintegrants and lubricants, and packaged in moisture-proof containers to maintain stability and minimize impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If compound A is administered orally, then patient compliance and convenience are improved, but stability and absorption are worsened due to high temperature instability and impurity formation
Solution Approach 1:
The patent uses specific excipients (microcrystalline cellulose, colloidal silica, pregelatinized starch) as intermediary substances to protect compound A from thermal degradation and environmental factors during oral administration. These excipients create a protective matrix that maintains compound stability without interfering with its analgesic and antipruritic effects
Solution Approach 2:
The invention formulates compound A as a composite pharmaceutical composition combining the active compound with stabilizing excipients. This composite structure provides thermal protection and improves stability while maintaining the therapeutic efficacy, enabling safe oral administration of the previously unstable compound
2Ease of operation
If compound A is formulated for oral administration, then convenience is improved, but manufacturing precision is worsened due to difficulty in controlling stability and impurity formation
Solution Approach 1:
The patent optimizes formulation parameters including excipient ratios, granulation conditions, and compression forces to achieve stable tablets. By carefully controlling these manufacturing parameters, the formulation maintains compound stability while enabling scalable production with consistent quality and minimal impurity formation
3Speed
If intravenous injection is used, then rapid onset of action is achieved, but patient compliance and convenience are worsened due to frequent administration requirements
Solution Approach 1:
The oral formulation is designed to achieve dissolution and absorption parameters that approximate the rapid onset of intravenous administration. Through optimization of particle size, excipient selection, and tablet formulation, the oral route achieves sufficiently rapid action to maintain therapeutic effectiveness while dramatically improving patient compliance
4Ease of operation
If oral formulation is developed, then patient compliance is improved, but absorption and irritation are worsened due to poor stability in oral environment
Solution Approach 1:
The excipients serve as mediators that protect compound A from degradation in the oral environment while facilitating its dissolution and absorption. The formulation creates a controlled release matrix that minimizes gastric irritation and ensures consistent bioavailability, achieving both improved compliance and maintained absorption
Data Source
AI summary
An oral pharmaceutical composition of a peptide amide compound A for treating pain and pruritus and a preparation method therefor. The composition comprises compound A and a microcrystalline cellulose colloidal silica co-treatment substance, and further comprises a disintegrant and/or a lubricant. The composition can be prepared into an oral preparation form such as a tablet or a capsule.